LinusBio vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 34)
LinusBio logo

LinusBio

EmergingLife Sciences & BioTech

AI-Powered Exposome Sequencing & Early Disease Diagnostics

LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors; focuses on early autism detection; spun out of MIT; raised $12.5M in Series A funding.

AI VisibilityBeta
Overall Score
D34
Category Rank
#166 of 198
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
36
Gemini
32

About

LinusBio is a precision medicine and diagnostics company founded by Manish Arora and headquartered in New York, with roots in research at the Icahn School of Medicine at Mount Sinai and MIT. The company has developed a proprietary technology platform called exposome sequencing — a method of analyzing biological samples, primarily hair, to reconstruct a detailed timeline of environmental exposures and biological changes over months or years. This approach enables early detection of disease risk factors by reading both genetic and environmental signals simultaneously.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#166
Category Rank
#11
87
AI Consensus
68
stable
Trend
stable
31
ChatGPT
71
36
Perplexity
68
32
Gemini
80
32
Claude
77
31
Grok
69

Key Details

Category
AI-Powered Exposome Sequencing & Early Disease Diagnostics
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.